CCI 779,
CCI-779,
rapamycin, 42-(3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate),
temsirolimus,
Torisel,
Temsirolimus,
CCI-779,
Torisel,
162635-04-3,
UNII-624KN6GM2T,
624KN6GM2T,
CHEMBL1201182,
42-[3-Hydroxy-2-methylpropanoate,
MFCD00934421,
NSC 683864,
NCGC00167518-01,
Cci 779,
Temsirolimus (CCI-779, NSC 683864),
WAY-CCI 779,
CHEBI:79699,
Temserolimus,
NSC-683864,
Temsirolimus - Torisel,
Rapamycin 42-(2,2-bis(hydroxymethyl)propionate),
Temsirolimus(CCI-779),
DSSTox_CID_20945,
DSSTox_RID_79605,
DSSTox_GSID_40945,
SCHEMBL18792,
42-(3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate)rapamycin,
42-[3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate]-rapamycin,
Rapamycin 42-[3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate],
Rapamycin, 42-(3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate),
GTPL5892,
DTXSID2040945,
HSDB 7931,
Temsirolimus, >=98% (HPLC),
CBPNZQVSJQDFBE-FUXHJELOSA-N,
C56H87NO16,
AOB87306,
Temsirolimus [USAN:INN:BAN:JAN],
Tox21_112515,
BDBM50343413,
s1044,
AKOS025142069,
AM84554,
RL02091,
NCGC00167518-02,
NCGC00167518-05,
RT-015903,
CAS-162635-04-3,
T3574,
AB01274736-01,
AB01274736_02,
635T043,
SR-01000898799,
J-009958,
SR-01000898799-3,
BRD-K08177763-001-02-6,
rapamycin,
Temsorolimus,
CS-O-02422,
A8314,
(1R,2R,4S)-4-{(2R)-2-[(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-1,5,11,28,29-pentaoxo-1,4,5,6,9,10,11,12,13,14,21,22,23,24,25,26,27,28,29,31,32,33,34,34a-tetracosahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontin-3-yl]propyl}-2-methoxycyclohexyl 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate,
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone 4'-(2,2-bis(hydroxymethyl)propionate),